Basic Information
SPERIKON (SPERIKON) was founded in 2023 as a high-tech enterprise specializing in the research and development of upstream reagents and CRDMO services in the CGT field. The company has innovatively established an "end-to-end" business model encompassing "reagents + processes + services." Leveraging its self-developed SP-EasyM personalized cell culture system development platform, it has pioneered nearly a hundred products, including serum substitutes with fully defined chemical compositions and fully CD-grade MSC culture media. The founding team hails from the Chinese Academy of Sciences, Peking University, and renowned domestic biopharmaceutical R&D institutions. Over 70% of the technical team holds a master’s degree or higher, combining expertise in cell biology, AI algorithms, and industrialization.